The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
_256_384.jpg)
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
